ACRV Latest Press Releases

-- November 6, 2026 --

Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKC? Inhibitor Preclinical Program from Aqilion AB Globe Newswire 8:00 AM

-- November 4, 2026 --

Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Globe Newswire 4:30 PM

-- October 29, 2026 --

Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium Globe Newswire 8:00 AM

-- October 20, 2026 --

Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 Globe Newswire 8:30 AM

-- September 2, 2026 --

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference Globe Newswire 8:00 AM

-- August 31, 2026 --

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer Globe Newswire 8:30 AM

-- August 12, 2026 --

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts Globe Newswire 4:05 PM

-- August 5, 2026 --

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study Globe Newswire 8:30 AM

-- July 21, 2026 --

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference Globe Newswire 4:30 PM

Market Data Delayed 15 Minutes